论文部分内容阅读
ＰｈａｒｍａｃｉａＣｏｒｐ公司的依立替康(ｉｒｉｎｏｔｅｃａｎ,ｃａｍｐｔｏｓａｒ)的新适应证获ＦＤＡ批准,与5氟尿嘧啶(5ｆｌｕｏｒｏｕｒａｃｉｌ)和叶酸(ｌｅｕｃｏｖｏｒｉｎ)(5ＦＵ/ＬＶ)联用治疗转移性直结肠癌。直结肠癌的主要治疗方案包括手术及辅助或不辅助化疗
PharmaciaCorp’s new indications for irinotecan (camptosar) have been approved by the FDA for the treatment of metastatic colorectal cancer in combination with 5-fluorouracil and leucovorin (5FU / LV). The main treatment options for colorectal cancer include surgery and chemotherapy with or without adjuvant chemotherapy